Piramal Life Sciences Limited

Radha Bhaskar Panicker

Bansi Lal

Asha Adrian Kulkarni-Almeida

Ravindra Dattatraya Gupte

Somesh Sharma

Swati Bal-Tembe

Sapna Parikh

Ashok Kumar Gangopadhyay

Tulsidas More

Usha Ghosh

Anagha Damre

Vadlamudi V S V Rao

Gopal Vishnu Gole

Sridevi Krishnan

Eleanor Pinto De Souza

Shashikant Patil

Pravin Gagare

Sunil Jadhav

Compounds of formula 1: are disclosed, wherein V is CH; W is S(O); m is the integer 0, 1 or 2; U is O, C(O), CRRor NR; where Ris H, alkyl; Ris H, OH, ORor OCOR; Ris H, alkyl, cycloalkyl, alkenyl, C(O)R, C(O)ORor alkylaminocarbonyl; R, R, R, R, R, R, Rand Rare as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-&#x3b1;) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-&#x3b1; activity, in particular inflammations.

Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein

Fibrinogen receptor antagonists and their use

Fused tricyclic compounds as inhibitors of tumor necrosis factor-&#x3b1;

This invention relates to novel fused bicyclic compounds of the general formula (I): whereinthe symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

Growing community of inventors

Mumbai, India

Radha Bhaskar Panicker